David Uguen

David Uguen

Company: Orchard Therapeutics

Job title: Senior Vice President, Regulatory Sciences

Seminars:

Gene Therapy Against Metachromatic Leukodystrophy – A European Registration Case Study 10:15 am

OTL-200 is an ex vivo autologous hematopoietic stem cell gene therapy approved by the European Medicines Agency (EMA) in 2020 and is currently the only approved treatment for MLD Appreciate the details of a successful EU registration procedure for a gene therapy to treat metachromatic leukodystrophy Hear about the various types of interactions with EMA…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.